Senate Amendment 5336 to Senate Concurrent Resolution 33
119th Congress(2025-2026)
To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.
Active
Not Agreed to in Senate on Apr 23, 2026
Origin Chamber
Senate
Type
Amendment
Amendment
A proposed change to a pending text (e.g., a bill, resolution, another amendment, or a treaty [or an associated resolution of ratification]).
Amendment Number
5336
Congress
119
Sort by most recent
04/23/2026
Senate amendment not agreed to: Amendment SA 5336 not agreed to in Senate by Yea-Nay Vote. 48 - 50. Record Vote Number: 103.
04/23/2026
Amendment SA 5336 not agreed to in Senate by Yea-Nay Vote. 48 - 50. Record Vote Number: 103.
04/23/2026
Amendment SA 5336 proposed by Senator Wyden. To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.
04/22/2026
Senate amendment submitted
Apr 23, 2026
Passed Senate
1
Sponsorship
Public Record
Record Updated
Apr 23, 2026 11:10:00 AM